Chemical formula: C₂₂H₃₁NO₃ Molecular mass: 357.486 g/mol PubChem compound: 4634
Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| G04BD04 | Oxybutynin | G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| KENTERA Transdermal patch | European Medicines Agency (EU) | MPI, EU: SmPC | |
| OXYTROL Transdermal system | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| LYRINEL XL Prolonged release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Oxybutinin is an active ingredient of these brands:
Austria (AT)Croatia (HR)Cyprus (CY)
Ecuador (EC)
Finland (FI)Germany (DE)
Israel (IL)
Italy (IT)Malta (MT)
New Zealand (NZ)Poland (PL)Singapore (SG)
South Africa (ZA)Turkey (TR)
United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
